A detailed history of Marks Group Wealth Management, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Marks Group Wealth Management, Inc holds 2,069 shares of ABBV stock, worth $378,482. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,069
Previous 2,148 3.68%
Holding current value
$378,482
Previous $368,000 10.87%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$163.84 - $199.33 $12,943 - $15,747
-79 Reduced 3.68%
2,069 $408,000
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $17,181 - $20,064
-111 Reduced 4.91%
2,148 $368,000
Q1 2024

Apr 29, 2024

BUY
$159.82 - $182.1 $799 - $910
5 Added 0.22%
2,259 $411,000
Q4 2023

Feb 01, 2024

BUY
$137.6 - $154.97 $8,668 - $9,763
63 Added 2.88%
2,254 $349,000
Q3 2023

Oct 30, 2023

BUY
$133.59 - $154.65 $667 - $773
5 Added 0.23%
2,191 $326,000
Q2 2023

Jul 19, 2023

SELL
$132.51 - $164.9 $84,143 - $104,711
-635 Reduced 22.51%
2,186 $294,000
Q1 2023

May 03, 2023

BUY
$144.61 - $166.54 $86,476 - $99,590
598 Added 26.9%
2,821 $449,000
Q4 2022

Feb 06, 2023

BUY
$138.31 - $165.87 $691 - $829
5 Added 0.23%
2,223 $359,000
Q3 2022

Nov 10, 2022

BUY
$134.21 - $153.93 $805 - $923
6 Added 0.27%
2,218 $297,000
Q2 2022

Aug 09, 2022

BUY
$137.62 - $174.96 $15,688 - $19,945
114 Added 5.43%
2,212 $339,000
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $33,390 - $41,428
253 Added 13.71%
2,098 $340,000
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $198,208 - $250,790
1,845 New
1,845 $249,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $323B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Marks Group Wealth Management, Inc Portfolio

Follow Marks Group Wealth Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marks Group Wealth Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Marks Group Wealth Management, Inc with notifications on news.